Autologous stem cell transplantation in patients who object to a blood transfusion: contribution of new pharmacological haematopoiesis support. (apre una nuova finestra)

Al-Nawakil C, Quarre MC, Heshmati F, Deau B, Park S, Dreyfus F, Bouscary D, Tamburini J.

Fonte‎: Br J Haematol 2013;161(5):738-40.

Indicizzato‎: PubMed 23480574

DOI‎: 10.1111/bjh.12284

https://www.ncbi.nlm.nih.gov/pubmed/23480574 (apre una nuova finestra)

A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. (apre una nuova finestra)

Al-Samkari H, Parnes AD, Goodarzi K, Weitzman JI, Connors JM, Kuter DJ

Fonte‎: Haematologica 2021;106(4):1148-57.

Indicizzato‎: PubMed 32499239

DOI‎: 10.3324/haematol.2020.251900

https://www.ncbi.nlm.nih.gov/pubmed/32499239 (apre una nuova finestra)

The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. (apre una nuova finestra)

Aribi A, Kantarjian H, Koller C, Thomas D, Faderl S, Garcia-Manero G, Cortes J.

Fonte‎: Cancer 2008;113(6):1338-43.

Indicizzato‎: PubMed 18629842

DOI‎: 10.1002/cncr.23718

https://www.ncbi.nlm.nih.gov/pubmed/18629842 (apre una nuova finestra)

Romiplostim efficacy in an acute myeloid leukemia patient with transfusion refractory thrombocytopenia. (apre una nuova finestra)

Berthelot-Richer M, Boilard B, Morin A, Bolduc B, Beauregard P, Kotb R.

Fonte‎: Transfusion 2012;52(4):739-41.

Indicizzato‎: PubMed 22082044

DOI‎: 10.1111/j.1537-2995.2011.03382.x

https://www.ncbi.nlm.nih.gov/pubmed/22082044 (apre una nuova finestra)

The role of interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors, lymphoma, acute myeloid leukemia and bone marrow failure syndromes. (apre una nuova finestra)

Bhatia M, Davenport V, Cairo MS.

Fonte‎: Leuk Lymphoma 2007;48(1):9-15.

Indicizzato‎: PubMed 17325843

DOI‎: 10.1080/10428190600909115

https://www.ncbi.nlm.nih.gov/pubmed/17325843 (apre una nuova finestra)

Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. (apre una nuova finestra)

Chawla SP, Staddon A, Hendifar A, Messam CA, Patwardhan R, Kamel YM.

Fonte‎: BMC Cancer 2013;13:121.

Indicizzato‎: PubMed 23497336

DOI‎: 10.1186/1471-2407-13-121

https://www.ncbi.nlm.nih.gov/pubmed/23497336 (apre una nuova finestra)

Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia (CIT) in a patient with mantle cell lymphoma. (apre una nuova finestra)

Demeter J, Istenes I, Fodor A, Paksi M, Dombi P, Valasinyószki E, Csomor J, Matolcsy A, Nagy ZG.

Fonte‎: Pathol Oncol Res 2011;17(1):141-3.

Indicizzato‎: PubMed 20628840

DOI‎: 10.1007/s12253-010-9276-4

https://www.ncbi.nlm.nih.gov/pubmed/20628840 (apre una nuova finestra)

Eltrombopag for radiation-induced thrombocytopenia in a glioblastoma patient. (apre una nuova finestra)

Duic JP, Grewal J, McConie K, Staszewski H, Haas J, Kesari S.

Fonte‎: J Neurooncol 2012;106(2):427-9.

Indicizzato‎: PubMed 21833801

DOI‎: 10.1007/s11060-011-0675-5

https://www.ncbi.nlm.nih.gov/pubmed/21833801 (apre una nuova finestra)

Recombinant human interleukin 11 and bacterial infection in patients with haematological malignant disease undergoing chemotherapy: a double-blind placebo-controlled randomised trial. (apre una nuova finestra)

Ellis M, Zwaan F, Hedström U, Poynton C, Kristensen J, Jumaa P, Wassell J, al-Ramadi B.

Fonte‎: Lancet 2003;361(9354):275-80.

Indicizzato‎: PubMed 12559860

https://www.ncbi.nlm.nih.gov/pubmed/12559860 (apre una nuova finestra)

Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. (apre una nuova finestra)

Ford PA, Grant SJ, Mick R, Keck G.

Fonte‎: J Clin Oncol 2015;33(15):1674-9.

Indicizzato‎: PubMed 25870085

DOI‎: 10.1200/JCO.2014.57.9912

https://www.ncbi.nlm.nih.gov/pubmed/25870085 (apre una nuova finestra)

Effect of avatrombopag in the management of severe and refractory chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors. (apre una nuova finestra)

Gao Y, Liu Q, Shen Y, Li Y, Shao K, Ye B, Shen Y, Zhou Y, Wu D

Fonte‎: Platelets. 2022 3;33(7):1024-1030.

Indicizzato‎: PubMed 35040375

DOI‎: 10.1080/09537104.2022.2026910

https://pubmed.ncbi.nlm.nih.gov/35040375/ (apre una nuova finestra)

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. (apre una nuova finestra)

Giagounidis A, Mufti GJ, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A, Gaidano G, Wiktor-Jedrzejczak W, Hu K, Woodard P, Yang AS, Kantarjian HM.

Fonte‎: Cancer 2014;120(12):1838-46.

Indicizzato‎: PubMed 24706489

DOI‎: 10.1002/cncr.28663

https://www.ncbi.nlm.nih.gov/pubmed/24706489 (apre una nuova finestra)

A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. (apre una nuova finestra)

Greenberg PL, Garcia-Manero G, Moore M, Damon L, Roboz G, Hu K, Yang AS, Franklin J.

Fonte‎: Leuk Lymphoma 2013;54(2):321-8.

Indicizzato‎: PubMed 22906162

DOI‎: 10.3109/10428194.2012.713477

https://www.ncbi.nlm.nih.gov/pubmed/22906162 (apre una nuova finestra)

Thrombopoietin-receptor agonists in haematological disorders: the Danish experience. (apre una nuova finestra)

Gudbrandsdottir S, Frederiksen H, Hasselbalch H.

Fonte‎: Platelets 2012;23(6):423-9.

Indicizzato‎: PubMed 22185370

DOI‎: 10.3109/09537104.2011.634931

https://www.ncbi.nlm.nih.gov/pubmed/22185370 (apre una nuova finestra)

Recombinant human thrombopoietin promotes platelet engraftment after haploidentical hematopoietic stem cell transplantation: a prospective randomized controlled trial. (apre una nuova finestra)

Han TT, Xu LP, Liu DH, Liu KY, Wang FR, Wang Y, Yan CH, Chen YH, Sun YQ, Ji Y, Wang JZ, Zhang XH, Huang XJ.

Fonte‎: Ann Hematol 2015;94(1):117-28.

Indicizzato‎: PubMed 25069650

DOI‎: 10.1007/s00277-014-2158-1

https://www.ncbi.nlm.nih.gov/pubmed/25069650 (apre una nuova finestra)

The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma. (apre una nuova finestra)

Jeong JY, Levine MS, Abayasekara N, Berliner N, Laubach J, Vanasse GJ.

Fonte‎: J Hematol Oncol 2015;8:37.

Indicizzato‎: PubMed 25886818

DOI‎: 10.1186/s13045-015-0136-2

https://www.ncbi.nlm.nih.gov/pubmed/25886818 (apre una nuova finestra)

Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. (apre una nuova finestra)

Kantarjian H, Fenaux P, Sekeres MA, Becker PS, Boruchov A, Bowen D, Hellstrom-Lindberg E, Larson RA, Lyons RM, Muus P, Shammo J, Siegel R, Hu K, Franklin J, Berger DP.

Fonte‎: J Clin Oncol 2010;28(3):437-44.

Indicizzato‎: PubMed 20008626

DOI‎: 10.1200/JCO.2009.24.7999

https://www.ncbi.nlm.nih.gov/pubmed/20008626 (apre una nuova finestra)

The use of simple patient blood management strategies as an alternative to platelet and red cell transfusion in autologous stem cell transplant. (apre una nuova finestra)

Locantore-Ford P, Grant SJ, Keck G.

Fonte‎: Blood 2013;122(21):2140.

https://www.bloodjournal.org/content/122/21/2140 (apre una nuova finestra)

The effect of recombinant human erythropoietin on platelet counts is strongly modulated by the adequacy of iron supply. (apre una nuova finestra)

Loo M, Beguin Y.

Fonte‎: Blood 1999;93(10):3286-93.

Indicizzato‎: PubMed 10233880

https://www.ncbi.nlm.nih.gov/pubmed/10233880 (apre una nuova finestra)

A single center experience with romiplostim for the management of chemotherapy-induced thrombocytopenia. (apre una nuova finestra)

Miao J, Leblebjian H, Scullion B, Parnes A

Fonte‎: Am J Hematol 2018;93(4):E86-E88.

Indicizzato‎: PubMed 29274130

DOI‎: 10.1002/ajh.25022

https://www.ncbi.nlm.nih.gov/pubmed/29274130 (apre una nuova finestra)

Pharmacological therapies to minimise platelet transfusion. (apre una nuova finestra)

Norfolk DR, Seghatchian J.

Fonte‎: Transfus Sci 2000;22(3):149-53.

Indicizzato‎: PubMed 10831916

https://www.ncbi.nlm.nih.gov/pubmed/10831916 (apre una nuova finestra)

Romiplostim for management of chemotherapy-induced thrombocytopenia. (apre una nuova finestra)

Parameswaran R, Lunning M, Mantha S, Devlin S, Hamilton A, Schwartz G, Soff G.

Fonte‎: Support Care Cancer 2014;22(5):1217-22.

Indicizzato‎: PubMed 24414994

DOI‎: 10.1007/s00520-013-2074-2

https://www.ncbi.nlm.nih.gov/pubmed/24414994 (apre una nuova finestra)

Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders. (apre una nuova finestra)

Pathak S, Roth M, Verma A, Steidl U.

Fonte‎: Expert Opin Drug Metab Toxicol 2013;9(12):1667-75.

Indicizzato‎: PubMed 24215532

DOI‎: 10.1517/17425255.2013.858119

https://www.ncbi.nlm.nih.gov/pubmed/24215532 (apre una nuova finestra)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (apre una nuova finestra)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Fonte‎: Leuk Lymphoma. 2019;60(9):2324-7.

Indicizzato‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (apre una nuova finestra)

Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. (apre una nuova finestra)

Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou TJ, Feigert J, Yeh SP, Götze K, Gorin NC, Greenberg P, Kambhampati S, Kim YJ, Lee JH, Lyons R, Ruggeri M, Santini V, Cheng G, Jang JH, Chen CY, Johnson B, Bennett J, Mannino F, Kamel YM, Stone N, Dougherty S, Chan G, Giagounidis A.

Fonte‎: Lancet Haematol 2015;2(10):e417-26.

Indicizzato‎: PubMed 26686043

https://www.ncbi.nlm.nih.gov/pubmed/26686043 (apre una nuova finestra)

Romiplostim for delayed platelet recovery and secondary thrombocytopenia following allogeneic stem cell transplantation. (apre una nuova finestra)

Poon LM, Di Stasi A, Popat U, Champlin RE, Ciurea SO.

Fonte‎: Am J Blood Res 2013;3(3):260-4.

Indicizzato‎: PubMed 23997988

https://www.ncbi.nlm.nih.gov/pubmed/23997988 (apre una nuova finestra)

Safety and efficacy of eltrombopag in post-hematopoietic stem cell transplantation (HSCT) thrombocytopenia. (apre una nuova finestra)

Raut SS, Shah SA, Sharanangat VV, Shah KM, Patel KA, Anand AS, Talati SS, Panchal HP, Patel AA, Parikh SK, Shukla SN.

Fonte‎: Indian J Hematol Blood Transfus 2015;31(4):413-5.

Indicizzato‎: PubMed 26306064

DOI‎: 10.1007/s12288-014-0491-0

https://www.ncbi.nlm.nih.gov/pubmed/26306064 (apre una nuova finestra)

Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. (apre una nuova finestra)

Reese JA, Li X, Hauben M, Aster RH, Bougie DW, Curtis BR, George JN, Vesely SK.

Fonte‎: Blood 2010;116(12):2127-33.

Indicizzato‎: PubMed 20530792

DOI‎: 10.1182/blood-2010-03-276691

https://www.ncbi.nlm.nih.gov/pubmed/20530792 (apre una nuova finestra)

Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. (apre una nuova finestra)

Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, Tamari R, Mitsiades CS, Verma A, Steidl U.

Fonte‎: Blood 2012;120(2):386-94.

Indicizzato‎: PubMed 22627766

DOI‎: 10.1182/blood-2011-12-399667

https://www.ncbi.nlm.nih.gov/pubmed/22627766 (apre una nuova finestra)

Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. (apre una nuova finestra)

Sekeres MA, Kantarjian H, Fenaux P, Becker P, Boruchov A, Guerci-Bresler A, Hu K, Franklin J, Wang YM, Berger D.

Fonte‎: Cancer 2011;117(5):992-1000.

Indicizzato‎: PubMed 20945323

DOI‎: 10.1002/cncr.25545

https://www.ncbi.nlm.nih.gov/pubmed/20945323 (apre una nuova finestra)

Romiplostim treatment of chemotherapy-induced thrombocytopenia. (apre una nuova finestra)

Soff GA, Miao Y, Bendheim G, Batista J, Mones JV, Parameswaran R, Wilkins CR, Devlin SM, Abou-Alfa GK, Cercek A, Kemeny NE, Sarasohn DM, Mantha S

Fonte‎: J Clin Oncol 2019;37(31):2892-8.

Indicizzato‎: PubMed 31545663

DOI‎: 10.1200/JCO.18.01931

https://www.ncbi.nlm.nih.gov/pubmed/31545663 (apre una nuova finestra)

Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. (apre una nuova finestra)

Stohlawetz PJ, Dzirlo L, Hergovich N, Lackner E, Mensik C, Eichler HG, Kabrna E, Geissler K, Jilma B.

Fonte‎: Blood 2000;95(9):2983-9.

Indicizzato‎: PubMed 10779449

https://www.ncbi.nlm.nih.gov/pubmed/10779449 (apre una nuova finestra)

A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine. (apre una nuova finestra)

Svensson T, Chowdhury O, Garelius H, Lorenz F, Saft L, Jacobsen SE, Hellström-Lindberg E, Cherif H.

Fonte‎: Eur J Haematol 2014;93(5):439-45.

Indicizzato‎: PubMed 24853277

DOI‎: 10.1111/ejh.12383

https://www.ncbi.nlm.nih.gov/pubmed/24853277 (apre una nuova finestra)

Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation. (apre una nuova finestra)

Tanaka T, Inamoto Y, Yamashita T, Fuji S, Okinaka K, Kurosawa S, Kim SW, Tanosaki R, Fukuda T.

Fonte‎: Biol Blood Marrow Transplant 2016;22(5):919-24.

Indicizzato‎: PubMed 26785333

DOI‎: 10.1016/j.bbmt.2016.01.018

https://www.ncbi.nlm.nih.gov/pubmed/26785333 (apre una nuova finestra)

Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. (apre una nuova finestra)

Tsimberidou AM, Giles FJ, Khouri I, Bueso-Ramos C, Pilat S, Thomas DA, Cortes J, Kurzrock R.

Fonte‎: Ann Oncol 2005;16(1):139-45.

Indicizzato‎: PubMed 15598951

DOI‎: 10.1093/annonc/mdi007

https://www.ncbi.nlm.nih.gov/pubmed/15598951 (apre una nuova finestra)

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. (apre una nuova finestra)

Wang ES, Lyons RM, Larson RA, Gandhi S, Liu D, Matei C, Scott B, Hu K, Yang AS.

Fonte‎: J Hematol Oncol 2012;5:71.

Indicizzato‎: PubMed 23190430

DOI‎: 10.1186/1756-8722-5-71

https://www.ncbi.nlm.nih.gov/pubmed/23190430 (apre una nuova finestra)

Romiplostim for chemotherapy-induced thrombocytopenia: efficacy and safety of extended use. (apre una nuova finestra)

Wilkins CR, Ortiz J, Gilbert LJ, Yin S, Mones JV, Parameswaran R, Mantha S, Soff GA

Fonte‎: Res Pract Thromb Haemost. 2022;6(3):e12701.

Indicizzato‎: PubMed 35582038

DOI‎: 10.1002/rth2.12701

https://pubmed.ncbi.nlm.nih.gov/35582038/ (apre una nuova finestra)

Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. (apre una nuova finestra)

Will B, Kawahara M, Luciano JP, Bruns I, Parekh S, Erickson-Miller CL, Aivado MA, Verma A, Steidl U.

Fonte‎: Blood 2009;114(18):3899-908.

Indicizzato‎: PubMed 19710504

DOI‎: 10.1182/blood-2009-04-219493

https://www.ncbi.nlm.nih.gov/pubmed/19710504 (apre una nuova finestra)